Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate 50% Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 30, 2026, 7:29 AM EDT
Recruiting Phase 2Phase 3 Interventional

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

NCT06101745
View directory record Official record
Conditions
Injury of Ureter During Surgery (Disorder)
Interventions
Nizaracianine Triflutate, Placebo Comparator
Drug
Lead sponsor
Curadel Surgical Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Redwood City, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

NCT00151281
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
PEPC, Thalidomide, Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Energy Imbalance on Food Intake Behaviors

NCT03112161
View directory record Official record
Conditions
Obesity
Interventions
Eucaloric Feeding Period, Overfeeding Feeding Period, Underfeeding Feeding Period
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 40 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 30, 2026, 7:29 AM EDT
Terminated Phase 1 Interventional

Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation

NCT02511041
View directory record Official record
Conditions
PGM3
Interventions
N-Acetylglucosamine (GlcNAc), Uridine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 7:29 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
12
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Acute Impact of Non-Sugar Sweeteners (Sucralose and Aspartame)

NCT07506564
View directory record Official record
Conditions
Prediabetes
Interventions
non-sugar sweeteners - Sucralose, non-sugar sweetener - aspartame, Non-sugar sweetener - control
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 7:29 AM EDT
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 30, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional

Effects of Ketosis on Brain Function in Patients With T1DM

NCT04219709
View directory record Official record
Conditions
Type1diabetes
Interventions
Very low carbohydrate diet, Standard carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 30, 2026, 7:29 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake

NCT04799301
View directory record Official record
Conditions
Diet Therapy, Healthy Volunteers
Interventions
Diet with no soda, Diet with 50% of carb intake from soda, Diet with 20% of carb intake from soda
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

NCT00004635
View directory record Official record
Conditions
Prostate Cancer
Interventions
Thalidomide, leuprolide acetate, goserelin, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
9
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 30, 2026, 7:29 AM EDT
Withdrawn Not applicable Interventional

Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT04088981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dietary intervention
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

NCT00600002
View directory record Official record
Conditions
Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
GM-CSF
Biological
Lead sponsor
Edward Nelson
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Not applicable Interventional Results available

Cocaine Withdrawal and Pharmacotherapy Response

NCT00566969
View directory record Official record
Conditions
Cocaine Dependence, Opiate Dependence
Interventions
sugar pill, Carvedilol 25 mg, Carvedilol 50 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 30, 2026, 7:29 AM EDT
Terminated Phase 2 Interventional

Asenapine for Bipolar Depression

NCT01807741
View directory record Official record
Conditions
Bipolar Depression
Interventions
Asenapine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

NCT00242203
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Zometa, Epirubicin, Docetaxel, Trastuzumab, External beam radiation, Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 30, 2026, 7:29 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04790903
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 30, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional

Living Well With Lymphoma

NCT06047626
View directory record Official record
Conditions
Lymphoma
Interventions
Fatigue Reduction Diet, General Health Curriculum
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 30, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

NCT05078138
View directory record Official record
Conditions
Exercise-Induced Anemia, Physical Performance
Interventions
Epoetin Alfa
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Sep 30, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

NCT05545306
View directory record Official record
Conditions
Obesity, Normal Physiology, Healthy Volunteers
Interventions
+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fasting, -50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein, -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Sep 30, 2026, 7:29 AM EDT
Terminated Phase 1 Interventional

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT03203525
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
Interventions
Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pegylated Liposomal Doxorubicin Hydrochloride, Temsirolimus, Tumor Treating Fields Therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 7:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

NCT03641768
View directory record Official record
Conditions
Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 30, 2026, 7:29 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 30, 2026, 7:29 AM EDT